Literature DB >> 1779972

Identification of a dominant negative form of the human estrogen receptor.

Y Wang1, R J Miksicek.   

Abstract

Experiments were undertaken to characterize mRNAs coding for the estrogen receptor (ER) in the human breast cancer cell line T47D. We report here the isolation of cDNAs corresponding to three isoforms of this receptor in addition to a majority of wild-type clones. Sequence analysis showed that these isoforms are generated through alternative splicing. None of the alternatively spliced isoforms of ER is able to bind to an estrogen-responsive element (ERE) in a gel mobility shift assay in vitro or to activate transcription of a reporter gene containing an ERE in vivo. One isoform, ER delta E3, which harbors a deletion of exon 3 encoding the second zinc finger of the DNA-binding domain, inhibits estrogen-dependent transcription activation in a dominant negative fashion when it is cotransfected with the wild-type ER and reporter plasmid. It also inhibits DNA binding of wild-type ER in a gel mobility shift assay in vitro. Since ER delta E3 is not able to bind to its response element, the observed inhibitory effect probably occurs through protein-protein interactions. This could involve the formation of a heterodimer between mutant and wild-type receptors, competition for a limiting transcription factor, or both. These results may have implications for understanding the loss of estrogen responsiveness that frequently occurs in breast cancer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1779972     DOI: 10.1210/mend-5-11-1707

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  40 in total

1.  Analysis of estrogen receptor messenger RNA in breast carcinomas from archival specimens is predictive of tumor biology.

Authors:  C Carmeci; E C deConinck; T Lawton; D A Bloch; R J Weigel
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Triple primer polymerase chain reaction. A new way to quantify truncated mRNA expression.

Authors:  E Leygue; L Murphy; F Kuttenn; P Watson
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

3.  A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1alpha gene.

Authors:  Yang-Sook Chun; Eunjoo Choi; Tae-You Kim; Myung-Suk Kim; Jong-Wan Park
Journal:  Biochem J       Date:  2002-02-15       Impact factor: 3.857

4.  Cytoplasmic estrogen receptor in breast cancer.

Authors:  Allison W Welsh; Donald R Lannin; Gregory S Young; Mark E Sherman; Jonine D Figueroa; N Lynn Henry; Lisa Ryden; Chungyeul Kim; Richard R Love; Rachel Schiff; David L Rimm
Journal:  Clin Cancer Res       Date:  2011-10-06       Impact factor: 12.531

5.  Estrogen regulates the expression of several different estrogen receptor mRNA isoforms in rat pituitary.

Authors:  K E Friend; L W Ang; M A Shupnik
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

6.  Steroid-regulated growth of DDT1MF-2 cells is profoundly influenced by culture conditions.

Authors:  D J Lamb; M Ray
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-12       Impact factor: 2.416

7.  Human small cell lung cancer cell lines expressing the proopiomelanocortin gene have aberrant glucocorticoid receptor function.

Authors:  D W Ray; A C Littlewood; A J Clark; J R Davis; A White
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

8.  Glucocorticoids and androgens up-regulate the Zn-alpha 2-glycoprotein messenger RNA in human breast cancer cells.

Authors:  Y S López-Boado; I Díez-Itza; J Tolivia; C López-Otín
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

9.  Exon skipping gives rise to alternatively spliced forms of the estrogen receptor in breast tumor cells.

Authors:  R J Miksicek; Y Lei; Y Wang
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

10.  The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain.

Authors:  S A Fuqua; D C Allred; R M Elledge; S L Krieg; M G Benedix; Z Nawaz; B W O'Malley; G L Greene; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.